Seth Y. Ablordeppey to Piperazines
This is a "connection" page, showing publications Seth Y. Ablordeppey has written about Piperazines.
Connection Strength
2.335
-
Ofori E, Onyameh EK, Gonela UM, Voshavar C, Bricker B, Swanson TL, Eshleman AJ, Schmachtenberg JL, Bloom SH, Janowsky AJ, Ablordeppey SY. New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263. Eur J Med Chem. 2021 Mar 15; 214:113243.
Score: 0.721
-
Onyameh EK, Bricker BA, Eyunni SVK, Voshavar C, Gonela UM, Ofori E, Jenkins A, Ablordeppey SY. A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice? Bioorg Med Chem. 2021 01 15; 30:115943.
Score: 0.714
-
Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019 04; 179:55-62.
Score: 0.628
-
Ablordeppey SY, Fischer JB, Glennon RA. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg Med Chem. 2000 Aug; 8(8):2105-11.
Score: 0.174
-
Bricker B, Jackson T, Boateng B, Zhu XY, Ablordeppey SY. Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav. 2012 Aug; 102(2):294-301.
Score: 0.098